Metoject Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing the production of tetrahydrofolate needed for DNA and RNA synthesis. This antiproliferative effect limits the growth of rapidly dividing immune and cancer cells and also dampens inflammatory pathways.

The dose of Metoject Pen is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here.

Methotrexate is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It is contraindicated during pregnancy and should not be used while breastfeeding, as it can be excreted in milk.

To order, submit an enquiry on the Metoject Pen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Compared with agents such as leflunomide or biologic TNF inhibitors, methotrexate offers a well‑established oral and subcutaneous route, a broad therapeutic window, and lower acquisition cost, but it requires regular laboratory monitoring for hepatic, renal and hematologic safety.

Metoject Pen should be stored at 2‑8 °C (refrigerated). Keep the pen in its original packaging, protect it from light, and do not freeze or shake the device. Do not use if the pen has been exposed to temperatures outside this range.

Metoject Pen is a pre‑filled, single‑use device for subcutaneous injection. The patient or healthcare professional removes the protective cap, selects the appropriate injection site (typically the abdomen or thigh), and presses the plunger to deliver the prescribed dose.

Serious risks include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, renal impairment, and profound bone marrow suppression leading to pancytopenia. Patients should report symptoms such as persistent nausea, shortness of breath, jaundice, or unusual bruising immediately.

Metoject Pen is contraindicated in pregnant or nursing women, patients with known hypersensitivity to methotrexate, those with severe hepatic or renal disease, and individuals receiving live vaccines. Caution is also advised for patients with existing blood dyscrasias.